US patient share leaders in first-line BRAF-mutation positive malignant melanoma
According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision Resources, Roche (ROC: SIX)/Genentech/Daiichi Sankyo/Chugai’s Zelboraf (vemurafenib) is the patient share leader in the first-line BRAF-mutation positive setting.
Surveyed oncologists also report that Bristol-Myers Squibb’s (NYSE: BMY) Yervoy (ipilimumab) holds the most patient share (around 50%) in the first-line BRAF wild-type setting; Yervoy also captures about one-third of patient share in second-line BRAF-mutation positive setting, according to surveyed oncologists. Respondents surveyed in third-quarter 2013 expect a significant decrease in the first- and second-line patient share of Zelboraf and Yervoy, respectively, within the next six months.
BRAF screening rates expected to increase
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze